SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-011123
Filing Date
2023-04-06
Accepted
2023-04-06 08:30:19
Documents
14
Period of Report
2023-04-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 57169
2 ex3-1.htm EX-3.1 64017
3 ex99-1.htm EX-99.1 147156
  Complete submission text file 0001493152-23-011123.txt   493021

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE rspi-20230403.xsd EX-101.SCH 3230
5 XBRL LABEL FILE rspi-20230403_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE rspi-20230403_pre.xml EX-101.PRE 22361
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3445
Mailing Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452
Business Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452 (201) 444-4947
RespireRx Pharmaceuticals Inc. (Filer) CIK: 0000849636 (see all company filings)

IRS No.: 330303583 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-16467 | Film No.: 23804452
SIC: 2834 Pharmaceutical Preparations